4.8 Article

PI3K-mTORC2 but not PI3K-mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma

Journal

CANCER RESEARCH
Volume 75, Issue 21, Pages 4617-4628

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-0708

Keywords

-

Categories

Funding

  1. Swedish Cancer Society
  2. Children's Cancer Foundation of Sweden
  3. Swedish Research Council
  4. Fru Berta Kamprads stiftelse
  5. SSF Strategic Center for Translational Cancer Research-CREATE Health
  6. VINNOVA
  7. BioCARE
  8. Strategic Research Program at Lund University
  9. Hans von Kantzows Stiftelse
  10. Gunnar Nilsson's Cancer Foundation
  11. Malmo University Hospital

Ask authors/readers for more resources

Hypoxia-inducible factor (HIF) is a master regulator of cellular responses to oxygen deprival with a critical role in mediating the angiogenic switch in solid tumors. Differential expression of the HIF subunits HIF1 alpha and HIF2 alpha occurs in many human tumor types, suggesting selective implications to biologic context. For example, high expression of HIF2 alpha that occurs in neuroblastoma is associated with stem cell-like features, disseminated disease, and poor clinical outcomes, suggesting pivotal significance for HIF2 control in neuroblastoma biology. In this study, we provide novel insights into how HIF2 alpha expression is transcriptionally controlled by hypoxia and how this control is abrogated by inhibition of insulin-like growth factor-1R/INSR-driven phos-phoinositide 3-kinase (PI3K) signaling. Reducing PI3K activity was sufficient to decrease HIF2 alpha mRNA and protein expression in a manner with smaller and less vascularized tumors in vivo. PI3K-regulated HIF2A mRNA expression was independent of Akt or mTORC1 signaling but relied upon mTORC2 signaling. HIF2A mRNA was induced by hypoxia in neuroblastoma cells isolated from metastatic patient-derived tumor xenografts, where HIF2A levels could be reduced by treatment with PI3K and mTORC2 inhibitors. Our results suggest that targeting PI3K and mTORC2 in aggressive neuroblastomas with an immature phenotype may improve therapeutic efficacy. (C) 2015 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available